ATC Group: B01AD10 Drotrecogin alfa (activated)

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B01AD10 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B01 Antithrombotic agents
3 B01A Antithrombotic agents
4 B01AD Enzymes
5 B01AD10 Drotrecogin alfa (activated)

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 40 mg

Active ingredients in B01AD10

Active Ingredient Description
Drotrecogin alfa

Drotrecogin alfa is a recombinant version of the natural plasma-derived activated Protein C, from which it differs only by unique oligosaccharides in the carbohydrate portion of the molecule. Activated Protein C is a crucial coagulation regulator. Furthermore, Activated Protein C is an important modulator of the systemic response to infection and has antithrombotic and profibrinolytic properties. Drotrecogin alfa has similar properties to those of endogenous human Activated Protein C.

Related product monographs

Title Information Source Document Type  
XIGRIS Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.